Pfizer and BioNTech announced Friday plans to add a third dose of the COVID-19 vaccine in an ongoing trial with young children, as the current two-dose regimen didn’t appear to be strong enough for ...

A slightly disappointing revenue outlook from Pfizer (PFE) was enough for its COVID-19 vaccine rivals Moderna (MRNA) and ...

This makes Pfizer a potentially cheap stock to buy while collecting a solid dividend. It's generated about $14 billion in ...

Pfizer Inc., the world's biggest drug maker, will change the label for its Viagra impotence pill to warn doctors about sudden vision loss that has occurred in some men who took the drug. The Food and ...

Pfizer is doing a little house cleaning of its pipeline, but not to worry. CEO Albert Bourla, Ph.D., is expecting to bring on external science that could help reap "at least $25 billion of ...

More than a year after Pfizer and venture capital company Flagship Pioneering struck a partnership investing in 10 life sciences programs, the two unveiled a collaboration with Quotient Therapeutics.

The next wave of genomic medicine is shaping up to include gene-editing therapies that do their work inside the patient, and Pfizer and Bayer each have new alliances that will broaden their reach to ...

Explore Pfizer Inc.’s 2025-2026 outlook: challenges, flat revenues, patent risks, and potential from the Metsera deal. Click for this updated look at PFE stock.

(Reuters) -The U.S. Food and Drug Administration said on Wednesday it plans to move quickly to add a warning about rare cases of heart inflammation in adolescents and young adults to fact sheets for ...

Experts say the ingredients in the COVID-19 vaccine developed by Pfizer and German partner BioNTech, which was authorized Friday by the U.S. Food and Drug Administration, looks pretty standard for a ...

This is an archived article and the information in the article may be outdated. Please look at the time stamp on the story to see when it was last updated. (NEXSTAR) – At the urging of the Food and ...

Texas Attorney General Ken Paxton is suing Pfizer and drug manufacturer Tris Pharma for fraud, alleging they provided “adulterated” attention deficit disorder medications to underprivileged children ...